Long-term safety of sugammadex in patients undergoing kidney transplantation.

Long-term safety of sugammadex in patients undergoing kidney transplantation: a single -center,large-scale,retrospective study.

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400081701

Enrollment

Unknown

Registered

2024-03-08

Start date

2024-03-10

Completion date

Unknown

Last updated

2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney transplantation

Interventions

Neostigmine group:None

Sugammadex sodium group:None

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age range: 18 to 65 years old; BMI 17~31.9 kg/m^2; ASA grade III or IV; Renal failure patients;

Exclusion criteria

Exclusion criteria: 1.incomplete medical records;previous cardiopulmonary insufficiency;coagulation disorder;combined multiple organ transplantation;kidney re-transplantation;living donor kidney transplantation;

Design outcomes

Primary

Measure	Time frame
patient survival;death-censored graft survival;complications;	—

Countries

China

Contacts

Public Contactwudiansheng

Second Affiliated Hospital of Guangzhou Medical University

597406505@qq.com+86 20 34152524

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026